5d 1m 3m 1y 5y 10y
Business Wire (Fri, 12:15PM)
Business Wire (Tue, 9:34AM)
Business Wire (Mar 3, 2014)
Business Wire (Feb 28, 2014)
at CNBC.com (Feb 27, 2014)
Business Wire (Feb 24, 2014)
Business Wire (Feb 24, 2014)
Business Wire (Feb 21, 2014)
at CNBC.com (Feb 18, 2014)
Business Wire (Feb 13, 2014)
at CNBC.com (Feb 6, 2014)
Business Wire (Feb 6, 2014)
at CNBC.com (Feb 5, 2014)
at CNBC.com (Jan 30, 2014)
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mLBusiness Wire (Jan 28, 2014)
at MarketWatch.com (Jan 21, 2014)
Marketwire (Jan 21, 2014)
Business Wire (Jan 21, 2014)
at CNBC.com (Jan 8, 2014)
at CNBC.com (Dec 30, 2013)
at CNBC.com (Dec 27, 2013)
at CNBC.com (Dec 27, 2013)
at CNBC.com (Dec 20, 2013)
TEVA vs. ETF Alternatives
Friday, Mar 710:31 AM
Thursday, Mar 67:52 AM
Tuesday, Mar 412:20 PM|Tuesday, Mar 412:20 PM| 1 Comment
Monday, Mar 310:50 AM
Monday, Mar 310:50 AM| 1 Comment
- Teva Pharmaceuticals (TEVA) is busily trying to convert users of its MS drug, Copaxone, to its new formulation that has patent protection until 2030 before competing generics launch in May.
- The new version requires thrice-weekly injections instead of daily.
- Copaxone delivers over 20% of the firm's revenues and 50% of its profit, so management is keen to preserve as much of the revenue stream as possible.
- The company offers a $1,000 discount from the current annual cost of $60,500 as an incentive to convert to the new version.
- Investors don't yet seem concerned about the issue since shares are up 23% year-to-date.
- Mutual fund ownership has eased from 1054 to 967 over the past four quarters.
Friday, Feb 218:10 AM|Friday, Feb 218:10 AM| Comment!
Sunday, Feb 162:56 AM
Sunday, Feb 162:56 AM| 2 Comments
- Teva (TEVA) has received a vote of confidence from George Soros, whose family office increased its stake in the Israeli pharmaceuticals company by 5.7M shares in Q4.
- The move boosted the value of Soros Fund Management's stake in Teva to $373M, or 4% of the $9.2B vehicle.
- The news comes after Teva named turn-around specialist Erez Vigodman as CEO in January.
Monday, Feb 108:56 AM
Monday, Feb 108:56 AM| Comment!
- U.S. authorities are investigating Teva (TEVA -0.7%) for possible violations of the federal False Claims Act in relation to the marketing and sales of the company's Copaxone and Azilect products.
- Teva received a subpoena on January 8 from the U.S. District attorney seeking documents and information from 2006 until the present in relation to the probe.
- Since 2012, Teva has been under investigation for the possible bribery of foreign officials. (SEC Filing)
Thursday, Feb 67:39 AM
Thursday, Feb 67:39 AM| Comment!
- Teva (TEVA) net profit rises to $380M from $320M.
- The 4.8% increase in revenue was primarily attributable to higher sales of generic medicines in the U.S., specialty medicines globally and OTC products. The rise was partially offset by a decrease in generics sales outside the U.S., mostly in Japan due to the weaker yen, and API sales to third parties.
- Revenue breakdown: total generics +1% to $2.7B; specialty medicines +5% to $2.2B. Copaxone +8% to $1.1B.
- Teve reaffirms its 2014 outlook.
- Declares 2013 dividend of 1.21 shekels ($0.34) a share, +5% from Q3. The record date will be February 24, and the payment date March 10. Tax will be withheld at a rate of 15%. (PR)
Thursday, Feb 67:02 AM|Thursday, Feb 67:02 AM| Comment!
Wednesday, Jan 294:57 AM
Wednesday, Jan 294:57 AM| Comment!
- Teva's (TEVA) shares are +2.7% in Tel Aviv after the FDA approved a 40 mg dose of the company's multiple sclerosis drug Copaxone that would be administered three times a week.
- Teva now plans to convert 57% of patients to the new regimen by the year-end from the daily dose of 20 mg.
- The longer-lasting regimen should help Teva cope with generic competition when Copaxone's patent protection expires in May. The higher-dosage version is protected until 2030. (PR)
Thursday, Jan 239:26 AM
Thursday, Jan 239:26 AM| Comment!
- Teva Pharmaceutical (TEVA -0.7%) intends to cut the size of its board and add directors with "global healthcare experience," Chairman Phillip Frost says in a letter to shareholders.
- The move is part of a wider review of corporate governance, which Frost says is a "priority."
- The letter comes after Teva recently hired turn-aroud specialist Erez Vigodman as CEO to replace Jeremy Levin, who resigned in October amid a reported difference of opinion with the company's board - and Frost specifically - over strategy.
Tuesday, Jan 217:30 AM
Tuesday, Jan 217:30 AM| Comment!
- NuPathe (PATH) has terminated its agreement to be bought by Endo Health Solutions (ENDP) and will instead recommend that shareholders approve Teva's (TEVA) offer of $3.65 a share, or approximately $144M.
- Endo had bid $2.85.
- Teva will pay another $3.15 a share depending on sales of Nupathe's Zecuity treatment, the only FDA-approved prescription migraine patch. Endo also offered that amount in milestone payments. (PR)
Tuesday, Jan 144:21 PM|Tuesday, Jan 144:21 PM| Comment!
Tuesday, Jan 143:37 PM
Tuesday, Jan 143:37 PM| 1 Comment
- Shares of Teva Pharmaceutical (TEVA +8.4%) are on their way to a solid session.
- The move higher is likely attributable to the reportedly upbeat tone struck at the JPMorgan Healthcare Conference, where the company presented today at 1:30 ET.
- According to chatter, the company says it is moving quickly with its new CEO.
- Also overheard during the presentation: The company is keeping the biosimilars business and remains interested in acquisitions.
- In other company news, TEVA says data published in the online scientific journal PLOS ONE suggests there are significant differences in biological and immunological effects between Copaxone and a purported generic." (PR)
Thursday, Jan 93:26 PM
Thursday, Jan 93:26 PM| Comment!
- "The selection of Vigodman -- who has been on Teva's (TEVA +0.9%) board of directors since 2009 -- is credit positive as it reduces the risk that there will be a significant departure from Teva's previously-stated strategy." Said strategy includes dealing with the patent expiration for Copaxone and implementing management's $2B cost reduction program, and Vigodman - seen as more of a turn-around guy than a pharmaceutical guy - seems to be a good fit for the job.
- There is no change to Teva's A3 rating or the negative outlook, says Moody's.
Thursday, Jan 93:20 AM
Thursday, Jan 93:20 AM| 1 Comment
- As expected, Teva (TEVA) has appointed board director Erez Vigodman as CEO to replace Jeremy Levin, who resigned in October.
- Vigodman has been CEO of MA Industries, the world's largest generic agrochemical company, since 2010. He led the firm's return to profitability by improving its day-to-day operations and investing in organic growth.
- Prior to that, Vigodman headed food company Strauss Group, whose sales doubled under his tenure.
- The challenges he faces at Teva include Copaxone's upcoming patent expiration and the implementation of a $2B cost-reduction program.
- Shares are -0.55% in Tel Aviv. (PR)
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.